Healthcare Industry News: oxandrolone
News Release - October 29, 2007
Savient Pharmaceuticals Announces Appointment of New VP Manufacturing
EAST BRUNSWICK, N.J.--(HSMN NewsFeed)--Savient Pharmaceuticals, Inc. (NASDAQ:SVNT ) announced today the appointment of Peter Clarke, Ph.D., to the newly-created position of Vice President, Manufacturing. In this role, he will oversee the company’s manufacturing activities and will report to Philip Yachmetz, Executive Vice President and Chief Business Officer.Dr. Clarke has over 25 years of biotechnology experience working in both manufacturing and research and joins Savient from Introgen Therapeutics, Inc., where he served as Vice President, Production and Technical Processes. From 2000 to 2004, Dr. Clarke held the position of Director of Manufacturing at Bayer Biologicals involved in the management of manufacturing activities at facilities in the U.S. and Europe and was closely involved in the North American and European licensure and launch of a novel immunoglobulin.
“We are very pleased to welcome Dr. Clarke to our team,” commented Philip Yachmetz. “Peter’s considerable experience and expertise with manufacturing and technical processes in the pharmaceutical industry will enable him to make valuable contributions as we continue to progress our manufacturing activities in support of our lead product candidate, Puricase®.”
Prior to joining Bayer, Dr. Clarke held the position of project manager with Medeva Pharma, the European Operations division of Medeva plc, a global pharmaceutical company, from 1998 to 2000. Prior to that time, he held various management positions in both start-up and established U.S. and European companies including Chiron SpA, Delta Biotechnology and ICI Biological Products. Dr. Clarke received his B.Sc. in biochemistry from Sheffield University in England. In addition, he received his Ph.D. in microbial physiology and DIC in biochemistry at the Imperial College of Science and Technology in London.
ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The Company's lead product development candidate, Puricase® for treatment-failure gout, has reported positive Phase 1 and 2 clinical data. Patient dosing in the Phase 3 clinical studies began in June 2006; patient enrollment was completed in March 2007, and the Phase 3 clinical studies were completed in October 2007. Pegloticase became the official generic name for Puricase assigned by the USAN Council replacing the previously used name of PEG-uricase. Savient's experienced management team is committed to advancing its pipeline and expanding its product portfolio by in-licensing late-stage compounds and exploring co-promotion and co-development opportunities that fit the Company's expertise in specialty pharmaceuticals and biopharmaceuticals with an initial focus in rheumatology. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. Further information on Savient can be accessed by visiting: http://www.savient.com.
Source: Savient Pharmaceuticals
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
